Welcome to our dedicated page for Evolus SEC filings (Ticker: EOLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evolus, Inc. filings document financial results and corporate disclosures for a Nasdaq-listed performance beauty company focused on aesthetic injectables. Its 8-K reports furnish quarterly and preliminary results, disclose capital-structure actions such as the termination of an at-the-market sales agreement, and record financing arrangements including a senior secured asset-based revolving credit facility.
The company’s proxy and current reports also cover governance and compensation matters, including a classified board structure, director reclassification, officer appointments and departures, equity award plans, executive compensation, shareholder meeting proposals, and related-party disclosures tied to its public-company reporting obligations.
Evolus, Inc. (EOLS) reported that President and Chief Executive Officer David Moatazedi sold 105,108 shares of common stock on September 2, 2026, in an open-market transaction at a weighted average price of $9.04 per share. Following this sale, he directly holds 499,592 shares of Evolus common stock.
Evolus, Inc. (EOLS) insider David Moatazedi filed a notice of proposed sale of company common stock under Rule 144. The filing lists up to 105,108 shares of Evolus common stock to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate value of $950,018.66 as of September 2, 2026.
The shares to be sold arise from various equity awards, including performance shares and restricted stock granted on dates in 2025 and 2026. The notice states that the issuer of all these securities is Evolus, Inc., and it is signed by David Moatazedi.
Evolus, Inc. (EOLS) has a new large shareholder group reported under Schedule 13G. A group of affiliated Soleus entities and Guy Levy report beneficial ownership of 3,480,000 shares of Evolus common stock, representing 5.3% of the class.
All 3,480,000 shares are held directly by Soleus Capital Master Fund, L.P., with Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy reporting shared voting and dispositive power and no sole power. The 5.3% figure is based on 66,050,440 shares outstanding as of July 31, 2026, as disclosed in Evolus’s Form 10-Q for the quarter ended June 30, 2026. Each reporting person disclaims beneficial ownership beyond what is required for Section 13(d) reporting.
Evolus, Inc., a performance beauty company focused on cash‑pay aesthetics, reported higher Q2 2026 net revenues of $84,084 thousand, up from $69,387 thousand a year earlier. For the first half of 2026, net revenues were $157,221 thousand with gross profit of $106,077 thousand.
The business remains unprofitable but losses narrowed. Q2 net loss was $8,052 thousand versus $17,142 thousand in 2025, and six‑month net loss was $18,726 thousand versus $36,034 thousand. Cash used in operating activities was $13,539 thousand, compared with $40,423 thousand, and results include a $1,949 thousand tariff‑refund receivable that reduced costs.
As of June 30, 2026, Evolus held $45,170 thousand in cash and cash equivalents, a stockholders’ deficit of $30,903 thousand, and long‑term debt of $156,744 thousand, mainly New Pharmakon Term Loans and a $10,000 thousand asset‑based revolver draw. Management believes existing cash, operations and committed credit facilities will fund operations for at least the next twelve months.
Evolus, Inc. reported second quarter 2026 net revenue of $84.1 million, up 21% year over year, driven by growth across U.S. and international injectable aesthetics. Gross profit margin was 68.0%, and adjusted gross profit margin was 69.0%.
The company recorded a GAAP operating loss of $4.5 million while delivering positive adjusted EBITDA of $4.7 million, its third consecutive quarter of positive adjusted EBITDA. Cash and cash equivalents were $45.2 million as of June 30, 2026.
Evolus raised its full‑year 2026 net revenue guidance to $330 million to $337 million, increased adjusted gross profit margin guidance to 67.0% to 67.5%, narrowed non‑GAAP operating expense guidance to $212 million to $216 million, and reaffirmed its 2028 outlook for $450 million to $500 million in net revenue and 13% to 15% adjusted EBITDA margins.
Evolus, Inc., through its subsidiary Evolus Pharma B.V., has amended its license, supply and distribution agreement with Symatese Aesthetics to add exclusive rights to commercialize the Estyme® injectable hyaluronic acid gel portfolio in Canada, Australia and New Zealand.
As consideration, Evolus Europe will pay €920,000 in upfront signing payments and up to an additional €1.38 million tied to regulatory approvals, while Symatese remains responsible, at its expense, for development and regulatory activities. The initial term in each new territory is 15 years from first regulatory approval, with automatic five-year renewals. Evolus targets commercialization in 2028, citing a combined neurotoxin and dermal filler market of about $500 million annually across these countries and expects the arrangement, including product transfer pricing and a mid-single digit royalty on net sales, to be accretive to international gross margins.
Evolus, Inc. entered into an exclusive License, Supply and Distribution Agreement with IBSA Institut Biochimique SA to develop, commercialize and distribute Profhilo®, an injectable hyaluronic acid product for skin-quality applications, in the United States aesthetics and dermatology markets.
Evolus will fund and manage U.S. development, clinical and regulatory work to seek FDA approval, then purchase product from IBSA under a transfer-price model with periodically adjustable terms. The agreement has no upfront or milestone payments, includes minimum purchase requirements starting in the fourth year after commercial launch, and runs for an initial 15-year term from first FDA approval with optional 5-year renewals. Management describes Profhilo® as a market-leading skin quality injectable abroad that complements Evolus’ existing neurotoxin and dermal filler portfolio and is not expected to change previously communicated 2026 and 2028 financial targets.
Evolus, Inc. reported the results of its Annual Meeting of Stockholders held on June 11, 2026. Stockholders elected Brady Stewart and Vikram Malik as Class II directors, each to serve until the 2029 annual meeting, with Stewart receiving 38,479,626 votes for and Malik 21,310,653 votes for.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 51,230,324 votes for. In addition, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers, with 39,350,651 votes for and 336,958 against.
Evolus, Inc. filed a shelf registration (Form S-3) that replaces an expiring registration and registers $195,519,553 of unsold securities from the prior registration and a base prospectus to offer up to $250,000,000 of common stock, preferred stock, debt securities, warrants, units and rights. The prospectus states the company may sell these securities from time to time and that the specific terms will be provided in prospectus supplements. The company notes its common stock trades on Nasdaq under the symbol EOLS and that the last reported sale price was $6.60 per share.